News

Roche invests in cancer immunotherapy

The Basel pharmaceutical company Roche will invest CHF 100 million into a cancer immunotherapy network. More than 20 academic centres will participate in the research network to advance the science of cancer immunotherapy.
Roche invests CHF 100 million in cancer immunotherapy.
Roche invests CHF 100 million in cancer immunotherapy.

The global cancer immunotherapy Centers of Research Excellence (imCORE) Network brings together 21 academic centres from around the world. According to a Roche statement, these leading academic research institutions will access and share technology, data and expertise on cancer immunotherapy. Their goal is to investigate the most promising new treatment approaches and develop new therapies that may one day offer a cure for people with cancer.

“We believe the fastest way to advance progress against cancer is through collaboration,” said Roche Chief Medical Officer Sandra Horning. “The goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world.”

Roche will invest up to CHF 100 million to support basic and clinical research collaborations related to cancer immunotherapy. Scientists from Genentech, a Roche subsidiary in the US, will also participate in the research network. The network will aim to take the most promising new treatment approaches to the clinical trial phase as rapidly as possible.

Read more
Recommend us

Related Content

Premium Partner

Strategic partners

Institutional partner

Official program